Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.71 |
| ▸ | S1PR3 | Q99500 | 18/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409065 | 0.94 | S1PR1 (0.80) | S1PR1S1PR3KCNH2 | |
| SCHEMBL10111666 | 0.91 | S1PR1 (0.66) | S1PR1S1PR3KCNH2 | |
| SCHEMBL2572204 | 0.90 | S1PR1 (0.80) | S1PR1S1PR3KCNH2 | |
| SCHEMBL407400 | 0.89 | S1PR1 (0.88) | S1PR1S1PR3KCNH2 | |
| SCHEMBL407630 | 0.89 | S1PR1 (0.80) | S1PR1S1PR3KCNH2 | |
| SCHEMBL410108 | 0.88 | S1PR1 (0.80) | S1PR1S1PR3KCNH2 | |
| SCHEMBL409100 | 0.87 | S1PR1 (0.81) | S1PR1S1PR3 | |
| SCHEMBL10111586 | 0.87 | S1PR1 (0.65) | S1PR1S1PR3KCNH2 | |
| SCHEMBL2571264 | 0.87 | S1PR1 (0.80) | S1PR1S1PR3KCNH2 | |
| SCHEMBL10111727 | 0.86 | S1PR1 (0.63) | S1PR1S1PR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | S1PR1, S1PR4, S1PR3 | S1PR1 1/4885S1PR3 3/4885KCNH2 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.